Medical network, June 26, after after A long period of low prices, since 2015, more than domestic vitamin products began to quietly raise, raised the "prices", only the a-share listed companies including new and into, hundred million sails medicine, medicine and so on six big zhejiang leading drug firms can earn dish, last year earned nearly $3 billion A year. According to the statistics, the net profit of the new and the net is the largest, over 1 billion yuan, and the growth of garden creature is the fastest, up to 262.52 %, while the gross profit rate of yifan medicine is the highest.
Outstanding performance in 2016 (unit: 10,000 yuan)
New and into
Xin and cheng is a company that mainly engages in the production and sales of nutrition, essence, new polymer materials and raw materials. The leading products of vitamin E, vitamin A, prawn, raspberry ketone and linalool are among the highest in the world. The company has become one of the world's four largest vitamin producers, a large national flavor and fragrance production enterprise and vitamin feed additive enterprises. In 2016, new and realized operating income was 469,627.73 million yuan, up 22.86% year on year. Net profit attributable to shareholders of listed companies was 120, 263.35 million yuan, up 199.11 percent year on year.
It is worth mentioning that new and formed in nutrition, is the pioneer of additive development, and successfully developed a variety of feeding and human additives. In the vitamin market share, the industry position is prominent, brand advantage is obvious. According to a 2016 annual report showed that the new and into methionine issue pilot run of success, to realize the strategic target of periodic at the same time, marked the methionine into mass production stage, the overall profitability and market competitiveness will be improved.
yifan
Yifan is mainly engaged in research and development, production and sales of pharmaceutical products, raw materials and polymer materials. Pharmaceutical products mainly include antibiotics, cardiovascular and cerebrovascular, skin and gynecological products. The main drug is vitamin B5 and the original B5 products; High polymer materials mainly include PBS and PVB products. The company achieved total operating income of 350,460.100,000 yuan, an increase of 43.93% year on year. Net profit attributable to listed company shareholders was 70,47627 million yuan, up 95.46 percent year on year.
According to the annual report, yifan is currently the world's largest producer and supplier of vitamin B5 and original B5 products, which are sold well in Europe and the United States, with a market share of 40-45%. At the same time, the company's enzymatic splitting method is the best technology in the world and its own intellectual property rights.
Zhejiang medicine
Zhejiang pharmaceutical main business is life nutrition, pharmaceutical products sales and pharmaceutical business. Life nutrition products mainly for synthetic vitamin E, natural vitamin E, vitamin A, vitamin H and other products; Pharmaceutical manufacturing products mainly for vancomycin hydrochloride, their stead ning, lumefantrine, artemether and other medicine material and "lixin" (levofloxacin lactate injection and its tablets), "credible" (vancomycin hydrochloride for injection), "lixin" (such as injection with their stead ning) pharmaceutical preparation, in addition, in 2016 achieved innovation medicine malic acid nai effect of active pharmaceutical ingredients and capsule production approval; Pharmaceutical business mainly company subordinates the medicine circulation enterprises in zhejiang province to profit pharmaceutical co., LTD., mainly distribution the winning drugs, to retail is complementary, scope of business includes: Chinese herbal medicine, Chinese medicine yinpian, proprietary Chinese medicine preparations, antibiotics, chemical medicine, biological products, narcotic drugs and so on. In 2016, zhejiang pharmaceutical realized operating income of 527,920.4 million yuan, a year-on-year increase of 17.40%, and the net profit attributable to the parent company was 45,010.2 million yuan, up 178.18% year on year.
Zhejiang pharmaceutical leading products synthetic vitamin E continuously improve production process, technical indicators further ascension, so is good situation, quantity and price based on synthetic vitamin E sales revenue grew by 46.80% year on year; The market price of vitamin A, another important profitable product, rose continuously, with sales up 93.00% year on year, and sales revenue of the company's life nutrition products increased 37.28 percent year on year. In addition, in 2016, drug marketing continued to strengthen academic promotion, actively expand the market, the sales volume of pharmaceutical products increased steadily, and the annual sales revenue of pharmaceutical preparations increased by 10.23% year on year.
Jin da wei
According to the annual report, jin da wei in the original animal nutrition, food nutrition fortifier industry raw materials and end products of health food production and sales business, on the basis of the movement of nutritional and functional food production, sales, business development. In 2016, the company realized its main business revenue of 166,275.08 million yuan, a year-on-year increase of 38.12%, and realized the net profit of the shareholders of listed companies was 29,976.79 million yuan, a year-on-year increase of 166.29%. The sales growth of the health products series increased by 304 million yuan, while the sales of vitamin A series increased by 22.4 million yuan, while the sales of coenzyme Q10 series decreased by 100 million yuan.
Brother technology
Brother technology is mainly engaged in research and development, production and sales of new fine chemical products such as vitamins and leather chemicals. Among them, vitamin products include vitamin K3, vitamin B1, vitamin B3 and vitamin B5 series products. In 2016, the operating revenue was 106,339.74 million yuan, up 17.46 percent year on year. The net profit attributable to the owner of the parent company was 16,766.84 million yuan, an increase of 103.87%.
It is worth mentioning that brother technology added phenol and its derivatives, contrast agents and its intermediate construction projects. Among them, the phenol and its derivatives are widely used in food, feed, medicine, cosmetics and other application fields. Contrast agent and its intermediates are widely used in X-ray examination. At present, the project is actively advancing, and with the completion and smooth implementation of follow-up projects, it will further expand its main business scope.
Garden organism
The main business of garden biology is the research and development, production and sales of vitamin D3 upstream and downstream products. After ten years of development, the company has now become a have vitamin D3 industrial chain integration of the unique advantages, at the same time production of NF levels of cholesterol and vitamin D3 series products, and production volume in the forefront of the global vitamin D3 industry well-known enterprises. In 2016, the company realized revenue of 32,909.38 million yuan, a year-on-year increase of 117.62%, and realized net profit of 4,377.28 million yuan, a year-on-year increase of 262.52%.
Biological garden according to the annual report, fundamental changes have taken place in product structure and income structure, changed the past an vitamin D3 products, the formation of cholesterol, 25 - hydroxy vitamin D3 and feed grade vitamin D3 go hand in hand, greatly improving the comprehensive profit ability and anti-risk ability.
Performance forecast (unit: 10,000 yuan) in the first half of 2017
Recently, 60 meters network reported a-share listed companies in the first half of 2017 net profit, net profit more than $500 million in six drug firms, among them, the vitamin enterprises accounted for two, respectively is new and into and sail medicine. While zhejiang medicine as early as in the first quarter of 2017 has said in the report, the company leading product synthesis of vitamin E market prices fall, is expected in the first half of the year, the cumulative net profit is greatly reduced compared with a year earlier.
Data source: listed company annual report, announcement |
